分支型Inoue支架行胸主动脉腔内修复术治疗主动脉弓动脉瘤的长期结局
动脉瘤相关死亡免除率在1年和5年均为93%,全因死亡免除率分别为85%和59%。单分支支架围术期结局可接受,多分支支架并发症有待改善。
要点
- 分支型Inoue支架治疗主动脉弓动脉瘤技术成功率高,单分支支架围术期结局可接受。
- 多分支支架围术期卒中风险较高,三分支支架30天死亡率达29%。
- 5年动脉瘤相关死亡免除率为93%,全因死亡免除率为59%。
核心结论
- 单分支Inoue支架的围术期结局可接受,长期安全性和有效性得到证实。
- 多分支Inoue支架的手术并发症仍有改善空间。
研究设计与样本
- 回顾性研究,纳入2003年3月至2013年9月连续接受Inoue支架胸主动脉腔内修复术的217例患者中的89例胸主动脉瘤患者。
- 支架类型:单分支64例,双分支18例,三分支7例。
- 主要终点为动脉瘤相关死亡免除率,次要终点包括围术期不良事件、全因死亡免除率、主要不良事件免除率、动脉瘤直径变化、卒中和再干预。
主要发现
- 所有分支型Inoue支架均成功释放。
- 30天死亡率为4.5%(单分支3.1%,双分支0%,三分支29%)。
- 围术期卒中发生率为16%(单分支7.8%,双分支33%,三分支42%)。
- 1年和5年动脉瘤相关死亡免除率均为93%,全因死亡免除率分别为85%和59%。
- 5年主要不良事件免除率为76%,卒中累积发生率为11%。
关键数值与推荐
- 3例患者因持续性I型内漏接受外科转换手术。
- 1例双分支支架患者出现左锁骨下动脉分支支架闭塞。
临床怎么用
- 对于适合的主动脉弓动脉瘤患者,单分支Inoue支架胸主动脉腔内修复术可作为可选方案。
- 多分支Inoue支架应用时需警惕围术期卒中和死亡风险,尤其三分支支架。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) for thoracic aortic aneurysms (TAAs) is in rapid expansion due to its minimal invasiveness. However, TEVAR for an arch aneurysm with a straight stent graft needs surgical reconstruction for supra-aortic vessels. A branched stent graft pioneered by Inoue (branched Inoue Stent Graft [ISG]) has been expected to resolve this problem, but its utility remains to be established in the real clinical setting. This study evaluated the long-term clinical outcome of branched ISGs for TAAs. METHODS: Among 217 consecutive patients who underwent TEVAR with ISGs between March 2003 and September 2013, 89 patients with TAAs were treated with implantation of the branched ISG (single branch: n = 64; double branch: n = 18; triple branch: n = 7). The primary end point was freedom from aneurysm-related death. Secondary end points included periprocedural adverse events, freedom from all-cause death and major adverse events (composite of aneurysm-related death, surgical conversion, aneurysm rapture, persistent type I or III endoleak, graft infection, graft occlusion, graft migration, and aneurysm expansion), changes of aneurysm diameter, stroke, and any endovascular reintervention during follow-up. RESULTS: All deployments of branched ISGs were successful. The 30-day mortality was 4.5% (single branch, 3.1%; double branch, 0%; triple branch, 29%), and periprocedural stroke was 16% (single branch, 7.8%; double branch, 33%; triple branch, 42%). At 1 and 5 years, freedom from aneurysm-related death was 93% and 93%, respectively, and freedom from all-cause death was 85% and 59%, respectively. Survival free of major adverse events was 76% at 5 years. The cumulative incidence of stroke was 11% at 5 years. Three patients underwent surgical conversion because of persistent type I endoleak. One branch graft occlusion was observed at the left subclavian artery in a patient who received a double-branched graft. CONCLUSIONS: Periprocedural outcome of the single-branched ISG was acceptable, and long-term safety and efficacy were demonstrated. However, the procedural complications of the multibranched ISG leave room for improvement.
引用
- Tazaki J, Inoue K, Higami H, et al. Thoracic endovascular aortic repair with branched Inoue Stent Graft for arch aortic aneurysms. J Vasc Surg. 2017. PMID: 28583734. doi:10.1016/j.jvs.2017.03.432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。